TG
RVNC

TCW Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

TCW Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-55,722
Closed -$1.08M – 735
2014
Q3 		$1.08M Sell
55,722
-2,651
-5% -$69.1K ﹤0.01% 700
2014
Q2 		$1.99M Buy
58,373
+14,291
+32% +$448K 0.01% 666
2014
Q1 		$1.39M Buy
+44,082
New +$1.38M 0.01% 697

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCW Group's RVNC Position: Q4 2014 in Review

TCW Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 55,722 shares — an estimated $1.08M sold.

TCW Group first reported a position in RVNC in Q1 2014 and held it in 3 quarters. The position peaked at $1.99M in Q2 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • TCW Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • TCW Group sold 55,722 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $1.08M.
  • TCW Group first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • TCW Group's Revance Therapeutics, Inc. position peaked at $1.99M in Q2 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on TCW Group's 13F filing for Q4 2014, filed 13 Feb 2015.